Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors.
Minghui HeDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-2422-0211
Roberta D'AulerioDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-8631-5625
Lia G PinhoDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0009-0008-1947-5635
Evangelos DoukoumopoulosDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0009-0001-0201-1585
Tracer YongDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-4009-3291
Rhaissa C VieiraDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-3695-5154
Mariana M S OliveiraDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-1268-1213
Laura EibenDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-5251-4439
Manon TermoteDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0009-0003-8333-3176
Rômulo G GalvaniDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-2946-375X
Saikiran SedimbiDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-5243-8395
Christina SeitzDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0009-0004-9475-3229
Nikolai V KuznetsovDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-3010-3927
Maria A ZuriagaCentro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid, Spain.ORCID 0000-0003-0422-2965
Daisuke KitamuraResearch Institute for Biomedical Sciences, Tokyo University of Science , Noda, Japan.ORCID 0000-0002-5195-0474
José J FusterCentro Nacional de Investigaciones Cardiovasculares (CNIC) , Madrid, Spain.ORCID 0000-0002-5970-629X
Vinicius Cotta-de-AlmeidaLaboratory for Thymus Research (LPT), Oswaldo Cruz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.ORCID 0000-0002-6753-3480
Lena StrömDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-8898-3675
Pia DosenovicDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-0426-4586
Søren E DegnDepartment of Biomedicine, Aarhus University, Aarhus C, Denmark.ORCID 0000-0001-5409-045X
Lisa S WesterbergDepartment of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-2943-2192
Funding
Agencia Estatal de InvestigaciónCAPESChildhood Cancer FundEuropean Social FundFundação para a Ciência e a TecnologiaInstituto de Salud Carlos IIIKarolinska InstitutetMinisterio de Ciencia, Innovación y UniversidadesOlle Engkvist ByggmästarePro CNIC FoundationRadiumhemmet Research FundsSevero Ochoa Center of Excellence CEX2020-001041-SSTINTSwedish Cancer SocietySwedish Research CouncilWenner-Gren FoundationsWorldwide Cancer Research
6 · The paper itself
Abstract
Activation-induced cytidine deaminase (AID) is essential for B cell affinity maturation. We investigated why AID deficiency gives rise to giant germinal centers (GCs) using the AIDR112H mouse model that is devoid of AID activity. The increased GC response was associated with accumulation of GC B cells in the light zone in immunized AIDR112H mice. AIDR112H GC B cells had reduced capacity to upregulate IRF4 to initiate plasma cell differentiation, leading to accumulation of a transitional GC population with reduced GL7 expression. Genetic introduction of a high-affinity B cell receptor was unable to restore plasma cell differentiation of AIDR112H B cells, while ectopic expression of catalytically active AID rescued plasma cell generation. AID and ten-eleven translocation 2 (TET2) synergistically facilitated demethylation of the Irf4 promoter/enhancer, and this was impeded in AIDR112H cells. These data reveal a B cell-intrinsic mechanism that governs the plasma cell fate decision through epigenetic remodeling mediated by AID in cooperation with TET2.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
AID and TET2 cooperate to demethylate Irf4 for plasma cell fate in germinal center B cells. · full record | OpenQuestion